PQ6A Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Starpharma Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.70 |
| 52 Week High | AU$1.09 |
| 52 Week Low | AU$0.52 |
| Beta | 0.76 |
| 11 Month Change | 32.08% |
| 3 Month Change | 23.89% |
| 1 Year Change | -11.39% |
| 33 Year Change | -88.86% |
| 5 Year Change | n/a |
| Change since IPO | -90.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQ6A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.7% | 1.4% | 0.8% |
| 1Y | -11.4% | -18.4% | 9.1% |
Return vs Industry: PQ6A exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.
Return vs Market: PQ6A underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| PQ6A volatility | |
|---|---|
| PQ6A Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQ6A has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: PQ6A's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 40 | Cheryl Maley | starpharma.com |
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It is also involved in the development of dendrimer enhanced product (DEP) delivery platform, consisting of DEP SN38 for the treatment of ovarian and colorectal cancer that is in Phase II clinical trial; DEP cabazitaxel for prostate and ovarian cancer treatment that is in Phase II clinical trial; and DEP docetaxel to treat pancreatic and other cancers that is in Phase II clinical trial.
Starpharma Holdings Limited Fundamentals Summary
| PQ6A fundamental statistics | |
|---|---|
| Market cap | €29.73m |
| Earnings (TTM) | -€5.06m |
| Revenue (TTM) | €6.04m |
4.9x
P/S Ratio-5.9x
P/E RatioIs PQ6A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQ6A income statement (TTM) | |
|---|---|
| Revenue | AU$9.76m |
| Cost of Revenue | AU$10.69m |
| Gross Profit | -AU$929.00k |
| Other Expenses | AU$7.24m |
| Earnings | -AU$8.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | -9.52% |
| Net Profit Margin | -83.69% |
| Debt/Equity Ratio | 2.8% |
How did PQ6A perform over the long term?
See historical performance and comparison